Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 25, 2016

Primary Completion Date

November 19, 2024

Study Completion Date

February 28, 2026

Conditions
OsteosarcomaEwing SarcomaRhabdomyosarcomaSoft Tissue Sarcoma
Interventions
DRUG

nab-Paclitaxel

nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)

DRUG

Gemcitabine

Gemcitabine: 1000 mg/m\^2 intravenously (IV)

Trial Locations (14)

19603

A.I. duPont Hospital for Children, Delaware - Nemours, Wilmington

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

28303

Carolinas Medical Center, Levine Cancer Institute, Charlotte

32207

Nemours Children's Clinic, Jacksonville

32608

Shand's Hospital for Children at the University of Florida, Gainesville

33136

Holtz Children's Hospital at the University of Miami, Miami

33612

H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center, Tampa

35294

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

37232

Vanderbilt - Ingram Cancer Center, Nashville

40506

University of Kentucky, Lexington

43205

Nationwide Children's Hospital, Columbus

90027

Children's Hospital Los Angeles, Los Angeles

06103

Connecticut Children's Medical Center, Hartford

All Listed Sponsors
collaborator

National Pediatric Cancer Foundation

OTHER

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER